Kling Biotherapeutics
Phase 1The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.
Founded
2020
Focus
AntibodiesBiologics
About
The company is headquartered in Amsterdam, Netherlands with a fully owned IP portfolio that covers platform technologies Kling-Select and Kling-Evolve for the simultaneous discovery of novel targets and identification of fully human antibodies directly from patient-derived B cells.
Funding History
1Total raised: $4.5M
Seed$4.5MBioGeneration VenturesJun 15, 2022
Company Info
TypePrivate
Founded2020
LocationLeiden, Netherlands
StagePhase 1
Contact
Sectors
SIMILAR COMPANIES
2-BBB Medicines
Pre-clinical · Leiden
Batavia Biosciences
Pre-clinical · Leiden
Bilthoven Biologicals
Pre-clinical · Bilthoven
Agendia
Pre-clinical · Amsterdam
Alloksys Life Sciences
Phase 2 · Wageningen
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile